UPC

363 articles available

The price of proofA confidentiality club is often discussed as though it were an access list. It is a judicial allocation of commercial risk. Most parties still treat it as the last item to settle,…

From remedy to orderFew disputes over UPC injunctions still turn on whether they will issue. The argument has moved to the terms of the order.The Court of Appeal has narrowed the first question with…

The USA truly is a land of innovation. One adult in eight there is currently taking a GLP-1 drug such as Ozempic or Wegovy.1 Within six months, their households spend 5.3% less on groceries and 8%…

In Sanofi and Regeneron v. Amgen, the Düsseldorf Local Division upheld a second medical use patent but dismissed the infringement action. The difficulty was proving that the medicine would be…

A second medical use patent is often seen as an easy target. The Milan section of the UPC Central Division has just shown that it is much harder to hit when the challenger is required to say exactly…

A divisional is worth what it allows its owner to argue later. G 1/25, and the referral now pending as G 1/26, sharpen a familiar point: that value comes from the choices made at filing and during…

The disclosure decision comes firstA comparable licence is never only evidence of a rate. Before the Unified Patent Court, pleading one may open it to an employee of the opponent, keep that employee…

A compass worth havingThe 7th Civil Chamber of the Landgericht München I has done something no European court had done before. On 13 August 2026 it published guidelines, sixty-seven pages long,…

Winning the jurisdiction argument in a long-arm case is not the same as having a claim. On 2 June 2026 the UPC Court of Appeal confirmed that the Mannheim Local Division had been right to hear…